Logan Capital Management Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% during the first quarter, Holdings Channel reports. The fund owned 28,050 shares of the company’s stock after buying an additional 715 shares during the period. Logan Capital Management Inc.’s holdings in Eli Lilly and were worth $2,359,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. BlackRock Inc. raised its position in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after buying an additional 708,597 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Eli Lilly and by 7.5% in the first quarter. UBS Asset Management Americas Inc. now owns 6,888,963 shares of the company’s stock worth $579,431,000 after buying an additional 482,576 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Eli Lilly and by 4.0% in the first quarter. Legal & General Group Plc now owns 4,964,536 shares of the company’s stock worth $417,597,000 after buying an additional 192,727 shares during the last quarter. Institutional investors own 75.61% of the company’s stock.

Eli Lilly and Company (NYSE:LLY) traded down 0.71% during trading on Thursday, reaching $81.98. The company’s stock had a trading volume of 314,441 shares. The company’s 50-day moving average is $83.02 and its 200-day moving average is $81.68. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The company has a market capitalization of $86.49 billion, a P/E ratio of 35.47 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS. Equities analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

TRADEMARK VIOLATION NOTICE: “Logan Capital Management Inc. Raises Position in Eli Lilly and Company (LLY)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/10/logan-capital-management-inc-raises-position-in-eli-lilly-and-company-lly.html.

A number of research analysts have weighed in on LLY shares. UBS AG lowered Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a report on Wednesday, July 26th. Piper Jaffray Companies restated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Monday, April 17th. Argus lowered Eli Lilly and from a “buy” rating to a “hold” rating and raised their price objective for the company from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC restated a “buy” rating and issued a $93.00 price objective on shares of Eli Lilly and in a report on Thursday, June 22nd. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 price objective on shares of Eli Lilly and in a report on Sunday, May 21st. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $88.27.

In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the sale, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock valued at $55,845,287 in the last quarter. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.